-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
A Shot of NVAX Stock Is NOT What Your Portfolio Needs
A Shot of NVAX Stock Is NOT What Your Portfolio Needs
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Novavax (NASDAQ:NVAX) stock hasn't had a great 2022, down 86% since the beginning of the year.
The company focuses on products to treat infectious diseases but is definitely best known for its Covid-19 vaccine NVX-CoV2373, also known as Nuvaxovid.
There are plenty of other competing vaccines in this category, and Novavax's shots haven't been strong sellers in the company's home market. A recent statement from President Joseph Biden certainly won't buoy Novavax's already dismal financial stats.
Assigning Novavax a "D" rating might seem harsh, but investors should acknowledge the facts. NVX-CoV2373 isn't the most commonly administered Covid-19 vaccine in the U.S. – not even close. This is problematic for a business that depends so heavily on its vaccine sales.
Furthermore, even the company's management seems to acknowledge that its Covid-19 vaccine sales aren't robust. Sorry to say it, but irrespective of the President's stance on the pandemic, there's no vaccine to protect against Novavax's poor financial performance.
NVAX Novavax $20.06What's Happening with NVAX Stock?
While the stock market's been under pressure in 2022, NVAX stock has been a particularly poor performer. The shares traded for $140+ at the beginning of the year, only to trade around $20 today.
Does this mean it's time to go n a bottom-fishing expedition? Definitely not, as Novavax has persistent problems that won't likely be resolved anytime soon.
Consider this: as of Sept. 17, nearly 225 million Americans received at least two Covid-19 vaccine doses. Of those, only 6,278 were vaccinated with Novavax's shots.
This poor performance is bound to have a negative impact on Novavax's next quarterly financial report. On that topic, Novavax's most recently reported quarter showed deep cracks in the company's foundation.
For one thing, Novavax posted $186 million in second-quarter 2022 revenue, a steep fall-off from the $298 million recorded in the year-earlier quarter. Also, Novavax's quarterly net earnings loss of $510 million was discernibly worse than the year-earlier quarter's $352 million loss.
The real kick to the gut, though, was Novavax's forward sales guidance. Alarmingly, the company reduced its full-year 2022 sales projection from $4 billion to $5 billion, to just $2 billion and $2.3 billion.
Trouble from the Top
You've probably seen this in the headlines by now: Biden declared that the Covid-19 pandemic is "over." It's been the topic of debate in traditional and social media for a while now.
No matter how you might feel about Biden's statement, it's important to be objective as an investor. There's no denying that the President's assertion is unfavorable for NVAX stock.
Indeed, Novavax shares lost 9% of their value soon after Biden said the pandemic is over.
It's yet another problem for a company that can't afford to have any more problems.
According to the Wall Street Journal, Novavax CEO Stanley Erck observed an "unexpected shortfall in demand for Covid-19 vaccines," while also acknowledging, "Demand is also uncertain in the U.S."
It's no wonder, then, that Novavax's management felt compelled to cut its full-year sales guidance in half. It also shouldn't be too surprising, then, that J.P. Morgan analysts downgraded NVAX stock from "neutral" to "underweight." One of J.P. Morgan's analysts, Eric Joseph, even sees "further guidance cuts … in the offing" for Novavax.
What You Can Do Now
Given Novavax's subpar Covid-19 vaccine sales and pitiful profit potential, it's difficult to give NVAX stock a positive rating. Moreover, even the company's CEO felt compelled to acknowledge that Covid-19 vaccine demand in the U.S. is waning.
Ultimately, Biden's statement about the pandemic being "over" is just one factor of many to consider. Still, it adds weight to an already compelling bearish argument, so it's prudent to refrain from investing in Novavax now.
On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
Louis Navellier, who has been called "one of the most important money managers of our time," has broken the silence in this shocking "tell all" video… exposing one of the most shocking events in our country's history… and the one move every American needs to make today.
The post A Shot of NVAX Stock Is NOT What Your Portfolio Needs appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市场新闻、股票建议和交易提示
Novavax (NASDAQ:NVAX) stock hasn't had a great 2022, down 86% since the beginning of the year.
诺华纳斯达克股票代码:NVAX)股价在2022年表现不佳,自年初以来下跌了86%。
The company focuses on products to treat infectious diseases but is definitely best known for its Covid-19 vaccine NVX-CoV2373, also known as Nuvaxovid.
该公司专注于治疗传染病的产品,但最出名的肯定是其新冠肺炎疫苗NVX-CoV2373,也被称为Nuvaxovid。
There are plenty of other competing vaccines in this category, and Novavax's shots haven't been strong sellers in the company's home market. A recent statement from President Joseph Biden certainly won't buoy Novavax's already dismal financial stats.
在这一类别中,还有许多其他竞争对手的疫苗,而Novavax的疫苗在该公司的本土市场并不畅销。总裁、约瑟夫·拜登最近的一份声明肯定不会提振诺华已经低迷的财务数据。
Assigning Novavax a "D" rating might seem harsh, but investors should acknowledge the facts. NVX-CoV2373 isn't the most commonly administered Covid-19 vaccine in the U.S. – not even close. This is problematic for a business that depends so heavily on its vaccine sales.
给予Novavax“D”评级可能看起来很苛刻,但投资者应该承认事实。新城疫CoV2373并不是美国最常用的新冠肺炎疫苗,差一点也不是。对于一个严重依赖疫苗销售的企业来说,这是一个问题。
Furthermore, even the company's management seems to acknowledge that its Covid-19 vaccine sales aren't robust. Sorry to say it, but irrespective of the President's stance on the pandemic, there's no vaccine to protect against Novavax's poor financial performance.
此外,就连该公司的管理层似乎也承认,其新冠肺炎疫苗的销售并不强劲。很抱歉这么说,但不管总裁对疫情的立场如何,没有疫苗可以预防诺华糟糕的财务表现。
What's Happening with NVAX Stock?
NVAX股票怎么了?
While the stock market's been under pressure in 2022, NVAX stock has been a particularly poor performer. The shares traded for $140+ at the beginning of the year, only to trade around $20 today.
虽然股市在2022年一直承压,但NVAX的股票表现尤其糟糕。今年年初,该公司股票的交易价格为140美元以上,但今天的交易价格约为20美元。
Does this mean it's time to go n a bottom-fishing expedition? Definitely not, as Novavax has persistent problems that won't likely be resolved anytime soon.
这是否意味着是时候进行一次海底捕鱼探险了?肯定不会,因为Novavax的问题持续存在,不太可能在短期内得到解决。
Consider this: as of Sept. 17, nearly 225 million Americans received at least two Covid-19 vaccine doses. Of those, only 6,278 were vaccinated with Novavax's shots.
考虑一下:截至9月1日。17日,近2.25亿美国人接种了至少两剂新冠肺炎疫苗。在这些人中,只有6278人接种了Novavax疫苗。
This poor performance is bound to have a negative impact on Novavax's next quarterly financial report. On that topic, Novavax's most recently reported quarter showed deep cracks in the company's foundation.
这种糟糕的业绩势必对Novavax的下一季财报产生负面影响。在这个话题上,Novavax最近公布的季度报告显示,该公司的基础存在严重裂痕。
For one thing, Novavax posted $186 million in second-quarter 2022 revenue, a steep fall-off from the $298 million recorded in the year-earlier quarter. Also, Novavax's quarterly net earnings loss of $510 million was discernibly worse than the year-earlier quarter's $352 million loss.
首先,Novavax公布的2022年第二季度营收为1.86亿美元,较去年同期的2.98亿美元大幅下降。此外,Novavax季度净收益亏损5.1亿美元,明显低于去年同期的3.52亿美元。
The real kick to the gut, though, was Novavax's forward sales guidance. Alarmingly, the company reduced its full-year 2022 sales projection from $4 billion to $5 billion, to just $2 billion and $2.3 billion.
然而,真正让人振奋的是Novavax的远期销售指引。令人担忧的是,该公司将2022年全年销售额预期从40亿美元下调至50亿美元,仅为20亿美元和23亿美元。
Trouble from the Top
来自顶端的麻烦
You've probably seen this in the headlines by now: Biden declared that the Covid-19 pandemic is "over." It's been the topic of debate in traditional and social media for a while now.
你现在可能已经在头条新闻中看到了这一点:拜登宣布新冠肺炎大流行已经“结束”。一段时间以来,这一直是传统媒体和社交媒体争论的话题。
No matter how you might feel about Biden's statement, it's important to be objective as an investor. There's no denying that the President's assertion is unfavorable for NVAX stock.
无论你对拜登的声明有何感想,作为一名投资者,保持客观是很重要的。不可否认,总裁的说法对NVAX股票不利。
Indeed, Novavax shares lost 9% of their value soon after Biden said the pandemic is over.
事实上,拜登说疫情结束后不久,Novavax的股价就下跌了9%。
It's yet another problem for a company that can't afford to have any more problems.
对于一家承受不起更多问题的公司来说,这是另一个问题。
According to the Wall Street Journal, Novavax CEO Stanley Erck observed an "unexpected shortfall in demand for Covid-19 vaccines," while also acknowledging, "Demand is also uncertain in the U.S."
根据《华尔街日报》,Novavax首席执行官斯坦利·厄克观察到“对新冠肺炎疫苗的需求意外下降”,同时也承认,“美国的需求也是不确定的。”
It's no wonder, then, that Novavax's management felt compelled to cut its full-year sales guidance in half. It also shouldn't be too surprising, then, that J.P. Morgan analysts downgraded NVAX stock from "neutral" to "underweight." One of J.P. Morgan's analysts, Eric Joseph, even sees "further guidance cuts … in the offing" for Novavax.
难怪Novavax的管理层不得不将全年销售指引削减一半。因此,摩根大通分析师将NVAX股票评级从中性下调至减持也就不足为奇了。摩根大通的分析师之一埃里克·约瑟夫甚至认为,诺华的“进一步指引将削减…”。
What You Can Do Now
你现在能做什么
Given Novavax's subpar Covid-19 vaccine sales and pitiful profit potential, it's difficult to give NVAX stock a positive rating. Moreover, even the company's CEO felt compelled to acknowledge that Covid-19 vaccine demand in the U.S. is waning.
鉴于诺华的新冠肺炎疫苗销量不佳,利润潜力也微乎其微,很难给诺华的股票一个正面的评级。此外,就连该公司的首席执行官也不得不承认,美国对新冠肺炎疫苗的需求正在减弱。
Ultimately, Biden's statement about the pandemic being "over" is just one factor of many to consider. Still, it adds weight to an already compelling bearish argument, so it's prudent to refrain from investing in Novavax now.
归根结底,拜登关于大流行即将结束的声明只是许多因素中需要考虑的一个因素。尽管如此,它还是为已经令人信服的看跌论调增添了份量,因此现在谨慎地不要投资Novavax。
On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
在文章发表之日,Louis Navellier和主要负责本文的InvestorPlace Research工作人员都没有(直接或间接)持有本文提到的证券的任何头寸。
Louis Navellier, who has been called "one of the most important money managers of our time," has broken the silence in this shocking "tell all" video… exposing one of the most shocking events in our country's history… and the one move every American needs to make today.
路易·纳维利耶,被称为“我们这个时代最重要的基金经理之一”,在这段令人震惊的“告诉所有人”的视频…中打破了沉默揭露了我国历史上最令人震惊的事件之一…这也是今天每个美国人都需要采取的行动。
The post A Shot of NVAX Stock Is NOT What Your Portfolio Needs appeared first on InvestorPlace.
在InvestorPlace上首次出现的帖子A Shoot of NVAX Stock is Not Your Portfolio Need。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧